The Medicines and Healthcare products Regulatory Agency (MHRA) approved a maximum dose of up to 7.2mg per week of semaglutide (Wegovy) on 6 January 2026.
Similar Posts
First major overhaul of medical device regulation comes into force across Great Britain
New Post-Market Surveillance (PMS) regulations have taken effect across Great Britain, requiring medical device manufacturers to proactively monitor the safety and performance of their products once on the market.
MHRA approves teplizumab to delay progression of type 1 diabetes
As with any medicine, the MHRA will keep the safety and effectiveness of teplizumab under close review.
MHRA launches a consultation on indefinite recognition of CE-marked medical devices
MHRA launches a consultation on indefinite recognition of CE-marked medical devices
Field Safety Notices: 28 July to 1 August 2025
List of Field Safety Notices from 28 July to 1 August 2025.
European first as MHRA approves over-the-counter allergy treatment for adolescents aged 12 and over
As with any medicine, the MHRA will keep the safety and effectiveness of fluticasone propionate under close review.
Fast, Expert and Open – how the MHRA is poised to become a global leader in risk-proportionate regulation
New MHRA CEO puts safety, accelerated access and innovation at the centre of agency’s refreshed strategic direction.